LYEL · Lyell Immunopharma, Inc.

Lyell Immunopharma Inc S A Late-Stage Clinical Cell Therapy Company Advancing A Pipeline Of Proprietary Next-Generation Autologous Chimeric Antigen Receptor (Car) T-Cell Product Candidates For Patients With Hematologic Malignancies And Solid Tumors. The Company'S Product Candidate, Rondecabtagene Autoleucel (Ronde-Cel, Also Known As Lyl314), Is An Autologous Dual-Targeting Cd19/Cd20 Car T-Cell Therapy In Development For Large B-Cell Lymphoma (Lbcl). The Company Has Recently Acquired Exclusive Rights Outside Of Mainland China, Hong Kong, Macau And Taiwan, To A Novel Guanylyl Cyclase C (Gcc)-Targeted Car T-Cell Product Candidate In Early Clinical Development For Refractory Metastatic Colorectal Cancer (Mcrc) And Other Gcc-Expressing Cancers.